Implantica (IMP) Q1 2025 earnings summary

Executive summary

• RefluxStop™ targets a vast market of acid reflux sufferers, offering a solution with fewer side effects and aiming to become the new standard of care, with over 1,200 surgeries performed in Europe and strong clinical outcomes.

• The company is developing an eHealth platform and other implantable devices, supported by a strong patent portfolio and future product plans.

• U.S. FDA approval for RefluxStop™ is targeted for late 2025, with favorable clinical data review and final module submission pending.

• Strategic U.S. launch planned with 50 initial centers, strong surgeon interest, and a price point of $7,800 per procedure.

• European expansion continues, with nearly 50 hospitals engaged and low complaint rates.

Financial highlights

• Q1 2025 net sales increased 25% year-over-year to EUR 745,000, driven by new and more active centers.

• Adjusted gross margin rose to 97% from 92% in the prior year period.

• Operating loss (EBIT) decreased by 41% to EUR 4.2 million, reflecting lower R&D and patent costs.

• Cash and short-term investments stood at EUR 60.3 million at March-end, with no interest-bearing debt.

• Shareholders’ equity at EUR 96.6 million as of March 31, 2025.

Outlook and guidance

• U.S. FDA approval for RefluxStop™ is expected in late 2025, with module three filing imminent and a normal review timeline suggesting possible approval by year-end.

• U.S. launch will target 50 centers of excellence, with phased expansion to 500 centers and favorable reimbursement.

• Targeting a 25-30% price premium in the U.S., with a price point of $7,800 per procedure.

• European expansion continues, with 1,200 surgeries performed and nearly 50 hospitals engaged.

• Continued evidence generation and payer engagement to drive reimbursement and market access.